Financials
Financial year 2025
Gross margin
€ 4.7 million
▼ 12% vs 2024
Profit
Healthy€ 57,526
▼ 16% vs 2024
Debts
Normal€ 1.4 million
▼ 14% vs 2024
Euthérapie Benelux from Anderlecht, company number BE0413600278, closed financial year 2025 with a result of € 57,526 after tax. For that financial year Euthérapie Benelux recorded a gross margin of € 4.7 million and equity of € 349,388. Compared with financial year 2024, the result moved from € 68,456 to € 57,526. The company is profitable. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on March 10, 2026.
What happened at Euthérapie Benelux?
What happened at Euthérapie Benelux in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 57,526 (▼ 16% vs 2024). Source: NBB ↗
- Ziad Matta stepped down as director. NBB
- Philippe Gonnard stepped down as director. NBB
- François Vilette stepped down as director. NBB
- Ziad Matta became a director. NBB
- Philippe Gonnard became a director. NBB
- François Vilette became a director. NBB
- New establishment in Anderlecht. KBO
In short
From € 93,530 profit in 2022 to € 57,526 profit in 2025.
Paid € 603,592 in corporate taxes since 2022.
Best year ever: 2023, with € 120,936 profit.
On average € 135,300 of value added per employee in 2025.
A new publication or filing at Euthérapie Benelux? We notify you, reason included.
Follow Euthérapie BeneluxNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
The shares are held by Biofarma (99.3%) and Les Laboratoires Servier (0.7%). It owns 0.1% of Daxispharma itself.
Directors
According to the 2025 annual accounts
since 2025 · until 2026
since 2025 · until 2026
since 2025 · until 2026
Shareholders
Biofarma
99.3%
Les Laboratoires Servier
0.7%
Participations
0.1%
Establishments
Establishment units
Physical locations of this company
Bergense Steenweg 1424
1070 Anderlecht
Internationalelaan 57
1070 Anderlecht
Active since 1 May 1974
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 12 companies are registered at this address.
HILTI BELGIUM
€ 99.8 million revenue · 2024
Servier Benelux same network
€ 89.1 million revenue · 2025
MANUTAN
€ 59.3 million revenue · 2025
DAXISPHARMA same network
€ 7.1 million gross margin · 2025
COCA-COLA EUROPACIFIC PARTNERS BELGIUM
€ 1,572.4 million revenue · 2025
+7 more
Details
- Company number
- 0413.600.278
- VAT number
- BE 0413.600.278
- Registered office
- Bergense Steenweg 1424, 1070 Anderlecht
- Names & denominations
- Euthérapie Benelux
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 1 April 1974
- Peppol
- Active · Active since 16 Jan 2026
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten